Pelthos Files Rule 425 Detailing Castle Creek Merger, $57.5M PIPE and Up to $300M Milestones
PTHS sits 41% above its 52-week low of $14.06 on light trading volume (0.3× avg).
Summary
Pelthos filed the Rule 425 communication for its all-stock merger with Castle Creek Biosciences, including 5,200,000 shares to Castle Creek holders, up to $300M in milestones, 5,800,000 contingent shares and a $57.5M PIPE that can reach $80M.
Key Events · M&A and Partnerships · PTHS
-
All-Stock Merger With Castle Creek
Pelthos issues 5,200,000 shares to Castle Creek holders, who are expected to own about 32.5% of Pelthos post-closing before the PIPE, with Pelthos holders at about 67.5%.
-
Up to $300M in Milestone Payments
Castle Creek holders can receive $50M on a D-Fi clinical milestone by June 30, 2029, $50M on first US commercial sale, $50M at $100M net sales, $75M at $250M and $75M at $500M, plus 5,800,000 contingent shares on FDA approval by March 31, 2036 and 80% of PRV proceeds.
-
$57.5M PIPE, Up to $80M
Investors including Ligand, Nomis Bay and Marshman are buying 57,500 Series B preferred shares at $1,000 stated value plus 496,951 warrants for about $57.5M; the option buyer can add up to $26.6M and other bridge buyers $1.5M before November 14, 2026, for a maximum of $80M.
-
Conversion Price and Voting Terms
Series B converts at $19.67 per share and votes as if converted at $16.54, with 150,000 shares authorized and 4.99%/9.99% ownership blockers.
Analysis · PTHS · Life Sciences
The full merger agreement is now on the record via this Rule 425 communication. Pelthos issues 5,200,000 shares to Castle Creek holders, who end up with about 32.5% of the combined company before the PIPE, plus up to $300M in cash milestones and 5,800,000 contingent shares tied to D-Fi approval by March 31, 2036. Funding comes from the $57.5M Series B PIPE at $1,000 stated value, convertible at $19.67, which can stretch to $80M if the option buyer and bridge holders participate by November 14, 2026. A re-rating is in play because the combined company now has a late-stage gene therapy asset (D-Fi for epidermolysis bullosa) and a funded balance sheet, but existing holders absorb meaningful dilution and the milestone payments are contingent on clinical and commercial success that is years away.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTHS was trading at $19.86 on NYSE in the Life Sciences sector, with a market capitalization of approximately $63.3M. The 52-week trading range was $14.06 to $37.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.